STUDY QUESTION: Do children born after donor ART have an increased risk of developing childhood cancer in comparison to the general population?
Introduction
Donor ART treatment cycles utilize donor sperm, oocytes or embryos and result in~10% of all births after ART in the UK (Human Fertilisation & Emryology Authority, 2013) . Given that most donors have few, if any, fertility problems, children born after donor ART represent a subtly different population than children born after non-donor ART. This inherent difference, together with the increasing use of donor ART cycles and the extra uncertainty faced by couples using donor gametes, places greater importance on follow-up studies differentiating between children born after donor and nondonor ART.
The possibility of an increased risk of childhood cancer in individuals born after ART has been suggested previously (Schieve et al., 2004; Sutcliffe and Ludwig, 2007; Kallen et al., 2010; Puumala et al., 2012; Hargreave et al., 2013) . Systematic reviews have provided conflicting evidence (Raimondi et al., 2005; Hargreave et al., 2013; Reigstad et al., 2017) , with a recent meta-analysis suggesting a small but significant increased risk of cancer in children born after ART (Relative Risk 1.33; 95% CI 1.08-1.63) (Hargreave et al., 2013) . Two large, populationbased studies, published since, reported no overall increased risk and no increased risk in haematological cancers (Williams et al., 2013; Sundh et al., 2014) . However, these studies did not include children born after donor ART (Williams et al., 2013; Sundh et al., 2014) . A further, smaller, population-based study showed no overall increased risk of childhood cancer, but did find a significant increase in leukaemia and Hodgkin lymphoma (Reigstad et al., 2016) . This study did include some children born after donor ART but did not estimate risk in this group separately (Reigstad et al., 2016) .
We conducted a large population-based linkage study, aiming to provide risk estimates for childhood cancer overall and for specific diagnostic subgroups (chosen a priori), in individuals born after donor ART.
Materials and Methods

Population and cohort participants
All records relating to 12 186 children born between 1 January 1992 and 31 December 2008 in Great Britain (England, Wales and Scotland) after donor ART were identified by the Human Fertilization and Embryology Authority (HFEA). Donor ART is defined as 'all treatments or procedures including in vitro handling of both human oocytes and sperm, or embryos, for the purpose of establishing a pregnancy' using donor oocytes, sperm or embryos (Zegers-Hochschild et al., 2009 ). The HFEA is legally required to record treatment and outcome details of all ART cycles in the UK, including those using donor gametes or embryos. Thus the dataset is considered effectively complete (HFEA act, 2008).
Ethical approval
Approval for the study was obtained from the National Information Governance Board and the London Research Ethics Committee including approval for the restricted use of data without individual written informed consent. One of the conditions attached to approval of this study prevents the publication of cells containing less than five individuals. Patients can withdraw consent for their HFEA data to be used for research. At the time of the study, 0.3% of all families using ART had done so; their data were not included.
Outcome data
Details of cancer incidence were obtained from the National Registry of Childhood Tumours (NRCT). During the study period, the NRCT was the largest national population-based childhood cancer registry world-wide, ascertaining validated information from multiple sources about children, under 15 years, diagnosed with cancer in the UK (Kroll et al., 2011) . The NRCT is considered almost complete for the study period (Kroll et al., 2011) . The International Classification of Childhood Cancer 3rd edition (ICCC-3), was used to categorize cancers (Steliarova-Foucher et al., 2005) . Co-morbidities, known at the time of a child's cancer diagnosis, were reported to the NRCT by the registering oncology centre, and data are reasonably complete for major congenital anomalies.
Data linkage
Ethical regulations stipulated that identifiable data were only viewed directly by HFEA staff. Therefore, data linkage was undertaken by two members of HFEA staff independently from each other, following a robust data linkage protocol, developed to maximize linkage sensitivity and specificity, used and described in another similar study (Williams et al., 2013) . 
Statistical analyses and calculation of expected rates
Person-years at risk were calculated from date of birth until the soonest of cancer diagnosis date, 31 December 2008 or the child's 15th birthday. There were 49 children (0.4%) excluded from the analyses as no valid date of birth was available and therefore person-years at risk could not be determined. Expected cancers in the cohort were calculated by multiplying person-years at risk by the corresponding national incidence rates (1-year age bands by calendar year and sex) for children born and diagnosed in Great Britain. Standardized incidence ratios (SIR) were calculated comparing observed cancers within the cohort to expected values. Exact 95% CIs and two-sided P-values were calculated assuming a Poisson distribution (Breslow and Day, 1987) . Analyses were performed using STATA software, version 12 (Stata Corp, 2013) .
Results
Included in the analysis were 12 137 children who contributed 95 389 person-years follow-up, with an average duration of 7.86 years. Cohort demographics are detailed in Table I .
Twelve children were linked to NRCT records and therefore identified as having developed cancer. Baseline demographics appeared broadly similar for cohort members who did and did not develop cancer (data not shown separately given the small numbers). The median age at cancer diagnosis was 2.6 years (inter-quartile range 1.2-5.2). There were no children with more than one cancer diagnosis. There were 14.4 cancers expected within the cohort, resulting in an unadjusted SIR of 0.83 (95% CI 0.43-1.45; Table II ). Sensitivity analysis including the two potential cases rejected during data linkage did not substantially alter the results (SIR 0.97; 95% CI 0.53-1.63; data not shown). The results did not change appreciably when stratified by sex, age at diagnosis, birthweight, birth multiplicity, maternal parity, type of ART, and fresh versus cryopreserved embryos (Table II) , although the small number of events in some strata have resulted in wider CIs.
No significant excess risk was seen for any major ICCC-3 category, with the exception of hepatic tumours (Table III) . A significant excess of hepatic tumours was detected (SIR 9.12; 95%CI 1.11-32.95; Table III ), all of which were hepatoblastomas (SIR 10.28; 95%CI 1.25-37.14; Table III; Absolute excess risk 18.66 per million personyears at risk, 95%CI 0.24-73.39). This excess was associated with low birthweight and was only seen in children with birthweight <2500 g (SIR 28.00; 95% CI 3.39-101.14; P = 0.02; data not shown).
Discussion
No overall increased risk of childhood cancer was detected in this large and complete national population-based cohort of children born after donor ART. This is in line with two similar recently published cohort studies of children born after non-donor ART (Williams et al., 2013; Sundh et al., 2014 on 91 796 children born after non-donor ART in four Nordic countries found no significant increase in overall cancer rates (adjusted Hazard Ratio 1.08; 95% CI 0.91-1.27) (Sundh et al., 2014) . Similarly our previous study of 106 013 children born after non-donor ART over the same study period and from the same population as our current study, did not show an overall increased risk of cancer (SIR 0.98; 95% CI 0.81-1.19) (Williams et al., 2013) . This study is the first, to the best of our knowledge, to explore cancer risk in children born after donor ART and uses high quality data from two population-based data sets. NRCT data are virtually complete for the study period (Kroll et al., 2011) and reporting to the HFEA is mandatory (HFEA act, 2008) . Whilst this study is the first to investigate cancer risk after donor ART, it is based on previously published methodology (Williams et al., 2013) . There were very few cases with uncertain linkage (n = 2), and sensitivity analysis including these did not substantially alter results.
Although this is a population-based study covering the whole of Great Britain over a 17 year time period which includes a large number of children born after donor ART, the rarity of specific diagnostic subgroups of childhood cancer and thus the small number of cases reported in this study result in wide CIs for individual outcomes. As this is an observational study, it is not possible to adjust for all potential confounders. We have instead used stratification to explore the role of a number of potential moderating and mediating factors, where data are available. Additionally, this study was not able to compensate for deaths and emigrations within this cohort. However, given the age of the cohort and extrapolating from national data (Office for National Statistics, 2010), we would estimate under normal circumstances not more than 69 members of the original cohort would have died during follow-up (0.6%). Emigration rates are harder to estimate, but we assume not more than 2% are likely to have emigrated during follow-up. It was not possible to adjust for socio-economic status (SES) as no measure of SES was available for the cohort as a whole. It is also possible that there were other unknown potential confounding factors, which we were unable to take into account. Whilst the overall numbers of children born after oocyte donation, sperm donation or embryo donation were available, these data were not available for analysis at an individual level. Our study had an average follow-up of 7.86 years. Therefore, we are not able to comment definitively on risk of cancer subtypes with a peak age of onset beyond 7 years. A significantly increased risk of hepatoblastoma was detected in this study of children born after donor ART, and was associated with low birthweight. A similar increased risk of hepatoblastoma, associated with low birthweight, was seen in our previous study of children born after non-donor conception (SIR 3.64; 95% CI 1.34-7.93) (Williams et al., 2013) . The Nordic group found a 2-fold increase risk of hepatic tumours in children born after non-donor ART; although this was based on small numbers and CIs were wide and included 1, they did find a hazard ratio of 2. ; adjusted for country, maternal age, parity, sex, gestational age and birth defects) (Sundh et al., 2014) . Beckwith-Wiedemann syndrome (BWS) is also a risk factor for hepatoblastoma (Puumala et al., 2012) , and children born after ART are at increased risk of BWS (Amor and Halliday, 2008) . There was a small number of children (less than five) in our cohort with BWS, but there were no cases of hepatoblastoma in children with BWS or related anomalies.
There is a known, consistent, inverse association between birth weight and hepatoblastoma risk (Ikeda et al., 1997; Tanimura et al., 1998; Ansell et al., 2005; McLaughlin et al., 2006; Spector et al., 2008 Spector et al., , 2009 et al., 2015) . Children born after ART are known to have significantly lower birth weight than children born after spontaneous conception (Helmerhorst et al., 2004; McDonald et al., 2010) . Unfortunately, as we were unable to adjust for birth weight, instead stratifying for this factor in both studies, we are unable to determine whether children in these studies have increased risk of hepatoblastoma mediated solely by to their low birth weight or whether children with low birth weight born after ART are at higher risk than they would be if born after spontaneous conception. The Nordic study did not adjust for birth weight directly, but adjusted for gestational age, which did not materially alter their rate estimate for hepatic tumours (Sundh et al., 2014) .
In conclusion, this study provides evidence against an increased risk of overall childhood cancer in individuals born after donor ART, which is reassuring for parents and clinicians alike. For the majority of individual diagnostic subgroups, risk estimates were not significantly raised. A significant increased risk of hepatoblastoma was observed, in line with that found in our recent study of children born after non-donor ART. This was associated with low birth weight, itself a known risk factor for hepatoblastoma. Although this finding was not observed in non-UK studies (Kallen et al., 2010; Sundh et al., 2014) , further investigation is warranted. However it should be emphasized that the absolute risks are very small. Cancer type classified according to ICCC-3 coding (Williams et al., 2013) . * = P < 0.05; ** = P < 0.01 and *** = P <0.001.
